Trastuzumab deruxtecan in the treatment of adult patients with HER-positive breast cancer

被引：0
|
作者：
Krzakowski, Maciej [1 ]
机构：
[1] Natl Oncol Inst Mar Sklodowska Curie, Natl Res Inst, Dept Lung & Chest Canc, Warsaw, Poland
来源：
ONCOLOGY IN CLINICAL PRACTICE | 2023年 / 19卷 / 05期
关键词：
D O I：
10.5603/ocp.97613
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：382 / 383
页数：2
相关论文
共 50 条
  • [41] Trastuzumab deruxtecan in breast cancer
    Martin, Miguel
    Pandiella, Atanasio
    Vargas-Castrillon, Emilio
    Diaz-Rodriguez, Elena
    Iglesias-Hernangomez, Teresa
    Cano, Concha Martinez
    Fernandez-Cuesta, Ines
    Winkow, Elena
    Perello, Maria Francesca
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 198
  • [42] A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer
    Nguyen, Xoan
    Hooper, Morgan
    Borlagdan, Jared Paul
    Palumbo, Alison
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (11) : 1410 - 1418
  • [43] Trastuzumab-deruxtecan and blood inflammatory markers in HER2-positive metastatic breast cancer
    Onishi, Mai
    Shimoi, Tatsunori
    Kitadai, Rui
    Tokura, Momoko
    Yazaki, Shu
    Sumiyoshi-Okuma, Hitomi
    Arakaki, Motoko
    Saito, Ayumi
    Kita, Syosuke
    Yamamoto, Kasumi
    Maejima, Aiko
    Kojima, Yuki
    Nishikawa, Tadaaki
    Sudo, Kazuki
    Noguchi, Emi
    Fujiwara, Yasuhiro
    Yonemori, Kan
    ANNALS OF ONCOLOGY, 2023, 34 : S1423 - S1423
  • [44] Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients
    Bighin, Claudia
    Pronzato, Paolo
    Del Mastro, Lucia
    FUTURE ONCOLOGY, 2013, 9 (07) : 955 - 957
  • [45] Trastuzumab and Deruxtecan Combination for Survival Benefit in Patients with HER2-low Breast Cancer
    Lichert, Frank
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (10)
  • [46] Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer
    Ishii, Takahiro
    Shitara, Kohei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) : 1193 - 1201
  • [47] Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
    Perez-Garcia, Jose Manuel
    Vaz Batista, Marta
    Cortez, Patricia
    Ruiz-Borrego, Manuel
    Cejalvo, Juan Miguel
    de la Haba-rodriguez, Juan
    Garrigos, Laia
    Racca, Fabricio
    Servitja, Sonia
    Blanch, Salvador
    Gion, Maria
    Nave, Monica
    Fernandez-Abad, Maria
    Martinez-Bueno, Alejandro
    Llombart-Cussac, Antonio
    Sampayo-Cordero, Miguel
    Malfettone, Andrea
    Cortes, Javier
    Braga, Sofia
    NEURO-ONCOLOGY, 2023, 25 (01) : 157 - 166
  • [48] DESTINY-Breast01 trial: trastuzumab deruxtecan in previously treated HER2 positive breast cancer
    Jackson, Emily B.
    Simmons, Christine E.
    Gelmon, Karen A.
    TRANSLATIONAL BREAST CANCER RESEARCH, 2021, 2
  • [49] Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
    Shitara, Kohei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-Hee
    Sakai, Daisuke
    Chung, Hyun-Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Yamaguchi, Kensei
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25): : 2419 - 2430
  • [50] Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
    Jerusalem, Guy
    Park, Yeon Hee
    Yamashita, Toshinari
    Hurvitz, Sara A.
    Modi, Shanu
    Andre, Fabrice
    Krop, Ian E.
    Farre, Xavier Gonzalez
    You, Benoit
    Saura, Cristina
    Kim, Sung-Bae
    Osborne, Cynthia R.
    Murthy, Rashmi K.
    Gianni, Lorenzo
    Takano, Toshimi
    Liu, Yali
    Cathcart, Jillian
    Lee, Caleb
    Perrin, Christophe
    CANCER DISCOVERY, 2022, 12 (12) : 2754 - 2762
12345